About Careers MedBlog Contact us

Mechanisms of Neuroblastoma Growth and Regression Deciphered

by Colleen Fleiss on December 12, 2018 at 3:17 AM
Font : A-A+

Mechanisms of Neuroblastoma Growth and Regression Deciphered

The genetic factors behind different neuroblastoma subtypes and their prognoses have been studied by researchers from CharitÚ - Universitńtsmediz in Berlin.

Peripheral nervous system tumors are one of the most common types of childhood tumors. While some of these tumors, known as neuroblastoma, disappear on their own without treatment, others will continue to grow even despite intensive treatment. Their findings enable clinicians to predict the precise clinical course of the disease, and to adapt their treatment regimens accordingly. The study has been published in the prestigious journal Science*.


One of the article's last-named authors, Prof. Dr. Johannes Schulte, of CharitÚ's Department of Pediatrics, Division of Oncology and Hematology, sums up the study's main findings as follows: "The data produced by our work provide us with a precise means of classifying different neuroblastoma phenotypes." Working alongside pediatric oncologists from University Hospital Cologne, in addition to various other colleagues, Prof. Schulte succeeded in deciphering the genetic code of neuroblastoma cells.

The researchers identified mutations in the RAS and p53 cancer signal transduction pathways - changes that are often associated with a poor prognosis. However, the researchers also found some cases of spontaneous tumor regression in patients with these mutations. It was only by merging the genetic data on these cancer signal transduction pathways with information on the mechanisms responsible for maintaining the length of telomeres (structures found at ends of our chromosomes) that the researchers gained a better understanding of the mechanisms involved in producing different neuroblastoma subtypes. This in turn enabled them to make precise predictions regarding disease prognosis.

Telomeres are known to act as a 'molecular clock' in human cells. In most of the body's cells, telomeres will shorten each time the cell divides. Once a critical length is reached, the cell receives the signal to stop dividing, resulting in cell growth arrest or cell death. Stem cells and most cancer cells, however, have telomere maintenance mechanisms which ensure that telomere length remains at above the critical length, thus effectively rendering the cell immortal.

Prognosis was found to be particularly poor in patients with additional mutations affecting the above-mentioned cancer signaling pathways. Given that current treatments are ineffective in the majority of these patients, the ultimate aim is to develop personalized treatments instead of applying unspecific therapies with severe side effects that will not help the patient.

Interestingly, in patients without telomere maintenance mechanisms, mutations of the cancer signaling pathways were found to have no bearing on prognosis. Many of these patients show spontaneous tumor regression even without treatment, while others have such a good treatment response that reduced regimens with less side effects may soon become feasible.

"Our study shows that the activation of telomere maintenance mechanisms plays a crucial role in the development of malignant tumors," says Prof. Schulte. The researchers' findings also provide an opportunity to explore and develop new treatment approaches. Targeted treatments that aim to block cancer signaling pathways and telomere maintenance mechanisms constitute one such promising new avenue.

Source: Eurekalert


Latest Cancer News

Could TKI Cancer Drugs Lead to Inflammatory Side Effects?
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Are Biomarkers the Key to Identifying Early Pancreatic Risk?
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
How Does New Drugs Work Together to Reduce Lung Tumors?
New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.
New Combination Therapy Proves Effective Against Prostate Cancer
Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.
Can Vitamin A Rich Diet Help Reduce Pancreatitis Risk
In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Mechanisms of Neuroblastoma Growth and Regression Deciphered Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests